Pharmaceutical giant AstraZeneca exceeded expectations with its figures for the second quarter. Shares rose sharply after the report.
The profit for the second quarter landed at $ 658 million, corresponding to approximately SEK 5.7 billion for the second quarter. That compares with profit of $ 866 million a year ago.
Earnings per share, excluding certain items affecting comparability, amounted to 1:21 dollars. Analysts had on average expected a profit of 1:05 dollars per share, according to Reuters.
Astra Zeneca adjusts its forecast for full-year sales and now expects a low single-digit decline in percent, measured in constant exchange. The forecast for profit is unchanged.
CEO Pascal Soriot writes in the report that he is particularly pleased with the development in oncology, where AstraZeneca has received new approvals for drugs Iressa and Faslodex. The Company has applied to have two new drugs in oncology approved. One of these, for the treatment of lung cancer, is expected to become a future bestseller with a potential annual sales of about 3 billion dollars.
At the Stockholm stock exchange closing had AstraZeneca’s share has risen by 3.4 percent.
No comments:
Post a Comment